What Is the Medicare Price for Ozempic in 2026?

Direct Answer: What Ozempic Costs on Medicare

It depends on your diagnosis and plan. Medicare Part D covers Ozempic only for type 2 diabetes, and most beneficiaries pay $25 to $150 per month in 2026 after meeting their deductible, capped at $2,100 in total annual drug costs. Without a diabetes diagnosis or Part D coverage, the cash price runs $935 to $998 per month. Starting January 2027, Medicare's negotiated price cuts that group price to roughly $274 to $277 per month.

What Determines Your Ozempic Price on Medicare

Medicare Part D is the only part of Medicare that can pay for Ozempic, because the drug is self-administered at home rather than given in a clinical setting. Original Medicare, meaning Medicare Part A (hospital insurance) and Medicare Part B (medical insurance) alone, does not include prescription drug coverage at all and cannot pay anything toward Ozempic, regardless of diagnosis.

Diagnosis code is the single biggest price lever. A 2003 federal law bars Part D from covering drugs prescribed solely for weight loss, so your prescriber must document a type 2 diabetes diagnosis (ICD-10 code E11.xx) for your Part D plan to apply its negotiated diabetes-drug pricing. Without that code, the claim is denied and you owe the full cash price. Formulary tier placement is the second lever: most Part D plans list Ozempic on Tier 3 or Tier 4, and higher tiers carry higher coinsurance percentages even after the diabetes diagnosis is approved.

Ozempic List Price vs. What You Actually Pay in 2026

Ozempic's wholesale acquisition cost (the manufacturer's list price before any rebates) sits at roughly $935.77 per month in 2026, and retail cash pharmacies typically charge closer to $998 once dispensing fees are added. Almost nobody with Part D coverage pays that full amount, because Part D benefit design splits the year into three phases with very different cost-sharing.

Coming January 2027: Medicare's Negotiated Ozempic Price

CMS selected Ozempic, together with Rybelsus and Wegovy (all semaglutide products from Novo Nordisk), for the second round of Medicare drug price negotiations under the Inflation Reduction Act. The negotiated price for the group is roughly $274 to $277 per month, a cut of about 71 percent from the $959 benchmark list price CMS used for comparison. That negotiated price takes effect January 1, 2027, and will apply to Part D claims for the diabetes indication.

CMS estimates more than 2.28 million Medicare beneficiaries used Ozempic, Rybelsus, or Wegovy, with combined 2026 Part D spending above $14.4 billion. The agency projects the negotiated price will save the Medicare program about $12 billion and cut Part D enrollee out-of-pocket spending by roughly $685 million in 2027. Separately, Novo Nordisk announced its own voluntary list price cut to $675 per month for all three semaglutide products, also effective January 1, 2027, though that change affects insurer list pricing rather than direct self-pay prices.

Medicare Advantage vs. Standalone Part D: Does Plan Type Change the Price

Medicare Advantage plans that bundle Part D coverage follow the same federal pricing rules as standalone Part D plans: the same $2,100 out-of-pocket cap, the same diabetes-only coverage rule, and the same three coverage phases. What differs is the formulary itself. One Medicare Advantage plan might place Ozempic on Tier 3 with a $47 copay, while a competing standalone Part D plan places it on Tier 4 with 25 percent coinsurance that could run over $100 per month during the initial coverage phase.

Medigap policies never factor into this comparison because Medigap only supplements Original Medicare's Part A and Part B cost-sharing and cannot cover prescription drugs under federal rules. If you carry a Medigap plan, you still need a separate standalone Part D plan to get any Ozempic coverage at all. During the Annual Enrollment Period (October 15 to December 7, 2026), compare each plan's exact Ozempic tier and copay using Medicare's Plan Finder before locking in coverage for 2027.

Extra Help Can Cut Your Ozempic Price to $12.65 or Less

Extra Help, also called the Part D Low-Income Subsidy, replaces your plan's standard deductible and copay structure with a fixed, much lower amount. In 2026, full-subsidy Extra Help recipients pay no more than $12.65 for a brand-name drug like Ozempic each month, and enrollees who are also fully dual-eligible for Medicaid and below the poverty line pay as little as $4.90 per month. Extra Help also eliminates the coverage-gap pricing entirely, so there is no deductible phase to get through first.

Income and resource limits determine eligibility, and the Social Security Administration processes most applications automatically for anyone who already has Medicaid, a Medicare Savings Program, or Supplemental Security Income. If you are not automatically enrolled, apply through the Social Security Administration or your state Medicaid office. See Medicare Extra Help income limits for the exact 2026 thresholds.

If Medicare Won't Cover It: Cash-Pay and Discount Alternatives

Medicare beneficiaries who need Ozempic for weight loss, or who have not yet met a diabetes-coverage prior authorization, have several ways to lower the cash price below the $935 to $998 retail range. Novo Nordisk's own NovoCare Pharmacy sells Ozempic directly for $349 per month at the 0.25 mg, 0.5 mg, and 1 mg doses, and $499 per month at the 2 mg dose, available to anyone paying cash regardless of Medicare enrollment. Discount programs such as GoodRx and SingleCare typically shave 10 to 20 percent off local retail prices and can be used alongside a cash purchase, though not combined with Part D billing.

Manufacturer copay cards, like the Novo Nordisk savings card that caps commercial insurance copays at $25, are federally prohibited for use by Medicare Part D beneficiaries under anti-kickback rules, so they will not reduce your Part D cost-sharing. Switching to Wegovy through the Medicare GLP-1 Bridge program is another path if your BMI and clinical history qualify, since Wegovy (not Ozempic) is one of the drugs eligible for the Bridge's $50 monthly copay starting July 2026. If you are not yet 65 or otherwise Medicare-eligible, ACA-compliant marketplace plans generally cover semaglutide for diabetes as an essential health benefit and cannot deny you coverage or raise your premium because of a preexisting condition such as diabetes.

• NovoCare Pharmacy direct self-pay: $349 to $499/month, no insurance required
• GoodRx or SingleCare discount cards: roughly 10 to 20 percent off retail cash price
• Medicare GLP-1 Bridge (Wegovy, not Ozempic): $50/month copay for qualifying BMI, starting July 2026
• Novo Nordisk Patient Assistance Program: free drug for qualifying low-income, uninsured patients
• Lower-tier alternative diabetes drugs: metformin or other GLP-1s may carry a lower copay on your plan's formulary

How much does Ozempic cost with Medicare Part D in 2026?

Most Medicare Part D beneficiaries with a type 2 diabetes diagnosis pay $25 to $150 per month for Ozempic in 2026, depending on their plan's formulary tier and coinsurance structure. You may pay full price ($935 to $998/month) during the deductible phase until your plan's deductible is met. Once your total annual drug spending reaches the $2,100 out-of-pocket cap, you pay $0 for the rest of the year.

Why does my Ozempic price depend on my diagnosis?

A 2003 federal law bars Medicare Part D from covering drugs prescribed solely for weight loss. Ozempic is only approved and covered under Part D for type 2 diabetes, so your prescriber must document a diabetes diagnosis (ICD-10 code E11.xx) for your plan to apply diabetes-drug pricing. Without that code, your claim is treated as a weight-loss prescription and denied, leaving you with the full cash price.

What will Ozempic cost under Medicare starting in 2027?

Medicare's negotiated price for the Ozempic, Rybelsus, and Wegovy group drops to roughly $274 to $277 per month starting January 1, 2027, under the Inflation Reduction Act drug price negotiation program. That is about a 71 percent cut from the $959 benchmark list price CMS used in the negotiation. Separately, Novo Nordisk announced a voluntary list price cut to $675 per month, also effective January 2027.

Does Medicare Advantage lower the price of Ozempic compared to standalone Part D?

Not automatically. Medicare Advantage plans with Part D coverage follow the same federal $2,100 out-of-pocket cap and diabetes-only coverage rule as standalone Part D plans. The actual price you pay depends on each individual plan's formulary tier for Ozempic, which can vary significantly between a Medicare Advantage plan and a competing standalone Part D plan in the same area.

What is Ozempic's cash price without Medicare coverage in 2026?

The retail cash price for Ozempic runs roughly $935 to $998 per month in 2026 without any insurance or Part D coverage. Novo Nordisk's direct NovoCare Pharmacy offers a lower self-pay price of $349 per month for the 0.25 mg, 0.5 mg, and 1 mg doses, and $499 per month for the 2 mg dose, available to anyone regardless of Medicare enrollment.

Can Extra Help lower my Ozempic Part D price?

Yes. Extra Help, the Part D Low-Income Subsidy, caps brand-name drug copays like Ozempic at $12.65 per month in 2026 for full-subsidy recipients, and as low as $4.90 per month for full-benefit dual-eligible enrollees below the poverty line. Extra Help also eliminates the deductible phase entirely, so you skip straight to the discounted copay.

Does the $2,100 Part D out-of-pocket cap apply to Ozempic?

Yes. The 2026 Medicare Part D annual out-of-pocket cap of $2,100, created under the Inflation Reduction Act, applies to your combined spending across all covered Part D drugs, including Ozempic. Once your total out-of-pocket spending on covered drugs reaches $2,100 in a calendar year, you pay $0 for the rest of the year.

Is there a generic version of Ozempic that costs less on Medicare?

No. There is no generic version of Ozempic (semaglutide) available in 2026, and Novo Nordisk's patents are expected to block generic entry until the mid-2030s. The main ways to lower your price on Medicare in 2026 are confirming your diabetes diagnosis code, applying for Extra Help, or comparing formulary tiers across Part D plans during Annual Enrollment.